补肾活血药对绝经后骨质疏松妇女血清骨代谢因子的调控作用

被引:31
作者
展磊 [1 ]
魏秋实 [2 ]
机构
[1] 广州市天河区前进街社区卫生服务中心
[2] 广州中医药大学第一附属医院骨科
基金
广东省自然科学基金;
关键词
中医中药; 补肾活血中药; 绝经后骨质疏松症; 骨代谢因子;
D O I
暂无
中图分类号
R580 [];
学科分类号
摘要
目的观察补肾活血中药对绝经后骨质疏松妇女血清骨代谢因子的调控作用。方法选择2012年7月2013年12月到广州市天河社区卫生院和广州中医药大学第一附属医院骨科门诊就诊的绝经后骨质疏松症患者共110例,所有患者均以钙尔奇D(600mg/日)作为基础药,将试验组(补肾活血中药+钙尔奇D)55例与对照组(钙尔奇D)55例进行比较研究。临床疗效评估指标包括VAS疼痛评分、不良反应、双能X线骨密度仪检测腰椎和股骨颈骨密度(BMD)、酶联免疫吸附法(ELISA)检测服用补肾活血中药治疗前后血清OPN浓度,电化学发光免疫分析法(ECLIA)检测血清25(OH)D、PINP和β-CTX的浓度。结果 (1)VAS疼痛评分:与治疗前相比,试验组VAS评分明显下降(P<0.01);对照组有一定程度降低,但无统计学意义(P>0.05)。(2)腰椎、左侧股骨颈的BMD:与治疗前相比,试验组腰椎、左侧股骨颈的BMD治疗后显著增加(P<0.05),对照组治疗前后比较均无显著性差异。(3)血清OPN、25(OH)D、PINP和β-CTX指标:与治疗前相比,试验组OPN、PINP和β-CTX浓度治疗后明显下降(均为P<0.05),25(OH)D浓度治疗后明显升高(P<0.05),对照组治疗前后各项指标间比较均无显著性差异。试验过程中,两组间均未见严重不良反应发生。结论补肾活血中药可缓解绝经后骨质疏松症患者疼痛症状,安全有效。它提高腰椎和股骨颈BMD的作用可能是通过降低血清OPN、PINP和β-CTX浓度,提高25(OH)D水平实现的。
引用
收藏
页码:1128 / 1132
页数:5
相关论文
共 16 条
[1]
Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis [J].
Li, Mei ;
Zhang, Zhen-lin ;
Liao, Er-yuan ;
Chen, De-cai ;
Liu, Jian ;
Tao, Tian-zun ;
Wu, Wen ;
Xia, Wei-bo ;
Lu, Yu-juan ;
Sheng, Zhi-feng ;
Lu, Chun-yan ;
Meng, Guo-ling ;
Xu, Liang ;
Zhang, Wei-jie ;
Hu, Ying-ying ;
Xu, Ling .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (01) :72-78
[2]
Halofuginone prevents estrogen-deficient osteoporosis in mice [J].
DeSelm, Carl J. ;
Zou, Wei ;
Teitelbaum, Steven L. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2012, 113 (10) :3086-3092
[3]
The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis [J].
Zhu, H. M. ;
Qin, L. ;
Garnero, P. ;
Genant, H. K. ;
Zhang, G. ;
Dai, K. ;
Yao, X. ;
Gu, G. ;
Hao, Y. ;
Li, Z. ;
Zhao, Y. ;
Li, W. ;
Yang, J. ;
Zhao, X. ;
Shi, D. ;
Fuerst, T. ;
Lu, Y. ;
Li, H. ;
Zhang, X. ;
Li, C. ;
Zhao, J. ;
Wu, Q. ;
Zhao, S. J. .
OSTEOPOROSIS INTERNATIONAL, 2012, 23 (04) :1317-1327
[4]
Five-year follow-up study of a kidney-tonifying herbal Fufang for prevention of postmenopausal osteoporosis and fragility fractures [J].
Deng, Wei-min ;
Zhang, Peng ;
Huang, Hai ;
Shen, You-gao ;
Yang, Qin-hua ;
Cui, Wei-li ;
He, Yang-shu ;
Wei, Song ;
Ye, Zhu ;
Liu, Fang ;
Qin, Ling .
JOURNAL OF BONE AND MINERAL METABOLISM, 2012, 30 (05) :517-524
[5]
Osteoporosis: now and the future [J].
Rachner, Tilman D. ;
Khosla, Sundeep ;
Hofbauer, Lorenz C. .
LANCET, 2011, 377 (9773) :1276-1287
[6]
Achyranthes bidentata root extract prevent OVX-induced osteoporosis in rats.[J].Rong Zhang;Shi-Jie Hu;Chen Li;Feng Zhang;Hong-Quan Gan;Qi-Bing Mei.Journal of Ethnopharmacology.2011, 1
[7]
Increased serum osteopontin is a risk factor for osteoporosis in menopausal women [J].
Chang, I. -C. ;
Chiang, T. -I. ;
Yeh, K. -T. ;
Lee, H. ;
Cheng, Y. -W. .
OSTEOPOROSIS INTERNATIONAL, 2010, 21 (08) :1401-1409
[8]
Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures [J].
McNamara, L. M. .
JOURNAL OF THE ROYAL SOCIETY INTERFACE, 2010, 7 (44) :353-372
[9]
Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe [J].
Siris, Ethel S. ;
Selby, Peter L. ;
Saag, Kenneth G. ;
Borgstrom, Fredrik ;
Herings, Ron M. C. ;
Silverman, Stuart L. .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (02) :3-13
[10]
Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States; 2005–2025.[J].Russel Burge;Bess Dawson‐Hughes;Daniel H Solomon;John B Wong;Alison King;Anna Tosteson.J Bone Miner Res.2006, 3